Novo Nordisk A/S
NVO
$65.77
$0.921.42%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.52% | 0.28% | 39.06% | -21.80% | 16.68% |
| Total Depreciation and Amortization | 4,564.69% | -96.35% | -30.18% | 44.49% | 232.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 152.68% | -157.76% | 43.94% | 595.40% | -49.20% |
| Change in Net Operating Assets | -1,552.92% | 91.55% | -226.39% | 193.87% | 10.42% |
| Cash from Operations | 97.32% | -72.79% | -11.33% | 249.63% | 51.16% |
| Capital Expenditure | 17.72% | -28.85% | -18.21% | -22.44% | 9.14% |
| Sale of Property, Plant, and Equipment | -- | -196.95% | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.40% | 170.44% | 6.47% | -176.48% | 336.10% |
| Cash from Investing | 92.78% | -323.20% | -2.98% | -619.30% | 127.11% |
| Total Debt Issued | -38.87% | 37,512.61% | -99.66% | -- | -- |
| Total Debt Repaid | -2,678.75% | 18.61% | 89.47% | -1,494.01% | 10.70% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 81.47% | -211.48% | 67.71% | -162.66% | 70.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | -- | 100.00% | -- |
| Other Financing Activities | -- | -- | -- | -200.00% | -- |
| Cash from Financing | -85.39% | 294.14% | -212.64% | 162.66% | -163.04% |
| Foreign Exchange rate Adjustments | -111.84% | 299.82% | -946.18% | -5.41% | 121.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.56% | -1,055.82% | -90.78% | 671.11% | 47.47% |